Nintedanib esilate impurity as well as preparation method and application thereof

A technology of nintedanib ethanesulfonate and ethanesulfonic acid is applied in the field of nintedanib ethanesulfonate impurity and its preparation, and can solve the problem of low yield, difficult purification of nintedanib ethanesulfonate impurity, and difficulty in obtaining Nintedanib ethanesulfonate and other problems, to achieve the effect of high yield, optimized solvent screening and good purity
CN110759848AInactive Publication Date: 2020-02-07JIANGSU HANSOH PHARMA CO LTD
7 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
JIANGSU HANSOH PHARMA CO LTD
Publication Date
2020-02-07
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a nintedanib esilate impurity as well as a preparation method and application thereof. By using the nintedanib esilate impurity, an analytic reference can be provided for detecting a nintedanib esilate product, the quality standard of nintedanib esilate can be improved, and the guarantee can be provided for the safe medication of nintedanib esilate.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of medicinal chemistry, and in particular relates to a nintedanib ethanesulfonate impurity and a preparation method and application thereof. Background technique

[0002] Nintedanib ethanesulfonate, chemical name: (3Z)-3-{[(4-{N-methyl-2-(4-methylpiperazin-1-yl)acetamido}phenyl)amino] (Phenyl)methylene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester ethanesulfonate, English name: Nintedanib Ethanesulfonate, manufactured by Boehringer Ingelheim (Boeringer Ingelheim), a multiple tyrosine kinase inhibitor developed to inhibit growth factor receptors associated with the pathogenesis of idiopathic pulmonary fibrosis (IPF). On October 15, 2014, nintedanib ethanesulfonate was approved by the US Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF) and non-small cell lung cancer.

[0003] The structural formula of nintedanib ethanesulfonate is as follows:

[0004] [000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More